How is CSI Innovative Drug Industry Index likely to move over the next seven days, and what position bias is appropriate?

The CSI Innovative Drug Industry Index is expected to experience moderate upward movement over the next seven days, driven by positive sector developments and a favorable policy environment. The dominant tension revolves around the balance between regulatory support and market sentiment, with recent policy announcements indicating continued backing for innovative drug development. The latest 24 hours have not produced any marginal changes that would significantly alter this outlook. The high-probability scenario suggests a positive impact from these factors, leading to a long position bias.

China's innovative-drug complex is in a structurally supportive regime: record 2026 out-licensing above US$120B year-to-date, global data recognition (WCLC, ESMO 2026), policy tailwinds, and the 931152 index still near one-year valuation lows. Yet the index surged 3.14% on Sept 14 and cooled on Sept 15 with rotation into semiconductors ('一日游'/'one-day trip') and ETF outflows (~0.8% dip), so short-term momentum is extended. With mixed catalysts ahead (ESMO 2026 data, the US FOMC decision, China's September LPR), the most plausible seven-day path is consolidation near the 1851.4 launch snapshot — an open-to-close move inside the ±1.5% band (~1824–1879). General position bias: NEUTRAL.

CSI Innovative Drug Industry Index (931152) enters the forecast week in an established correction: its tracking ETF has fallen more than 10% since mid-August and sits below its early-January 2026 level, while the broad A-share market is in a low-volume pre-National-Day consolidation that analysts expect to persist. Structural policy support (biopharma as a pillar industry, Essential Drug List inclusion effective Sep 1, the 2026 NRDL and commercial-insurance innovative drug catalog negotiation running since Sep 5, and continued BD out-licensing) limits deep downside but has not stopped the slide. The dominant tension for the next seven days is whether this policy support can offset macro headwinds, and the key event resolving it is the Sep 15-16 FOMC, where economists polled by Reuters now expect a 25bp HIKE under hawkish Chair Warsh, with the decision landing 02:00 Beijing on Sep 17 - inside the window. A hike with a hawkish dot plot would pressure rate-sensitive growth/biotech globally and reinforce the local downtrend; the last 24 hours (Sep 15 broad decline, sector ETF down ~1-1.5%, weak-bottoming guidance) strengthen rather than weaken that bearish skew. Base case is a continued weak grind exceeding -1.5% over the seven-day open-to-close window, hence a SHORT bias, while acknowledging the hold/relief-rally path and NRDL news flow keep NEUTRAL and LONG materially alive.

The structural regime for the CSI Innovative Drug Industry Index (931152) is a policy-supported, globalization-driven sector that in 2026 has shifted from narrative to delivered earnings: brokerage reviews of the H1 2026 reporting season describe the innovative-drug value chain as sustaining high prosperity, with BD/licence-out catalysts compounding domestic medical-insurance payment reform. Against that improving micro, 2026 price action has been range-bound rather than trending, because global duration risk keeps compressing the multiple: as of 14 September the index traded at 41.4x PE-TTM, in only the 2.72nd percentile of its trailing year, i.e. cheaper than 97% of the last twelve months despite the earnings upgrade. That gap is the dominant unresolved tension for the coming week, and it is being arbitrated by a hostile global macro: the FOMC meets 15-16 September with roughly 90% market-implied odds of the first rate hike since 2023, after a hawkish Jackson Hole message and an Iran/energy-driven inflation impulse. Marginal 24-hour check: on 14 September WCLC readouts from Chinese developers drove a sharp sector rally, lifting 931152 2.52% with CRO/CXO names leading; on 15 September the A-share market reversed into a low-turnover drift (Shanghai Composite -0.54%, ChiNext -1.15%, aggregate turnover shrinking to roughly RMB 1.63trn, near a year low) as investors de-risked ahead of the Fed. Net: fundamentals mildly reinforced, flows mildly cautious, no verified reversal of the mainline. Because the 1851.41 launch snapshot sits on a deeply discounted multiple, because the resolution window opens on a base already softened by the 15 September pullback, and because the 29th CSCO annual congress (17-19 September, Jinan) is an in-window, sector-specific data and deal catalyst that lands immediately after the Fed event risk clears, I favour a modest long position bias for the week to 23 September, while acknowledging that a high-beta basket like this one has a weekly volatility wide enough that the neutral band is genuinely reachable.